CATALYST PHARMACEUTICALS, INC. 4

Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, Inc., had 4,171,559 common shares, vested options over 2,431,322 shares, and 17,626 RSUs cashed out at an effective $31.50 merger price on July 15, 2026.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. Chairman of the Board Patrick J. McEnany disposed of all his equity interests in connection with the cash acquisition of the company by Angelini Pharma S.p.A. at $31.50 per share. This included 4,171,559 shares of common stock converted into cash at $31.50 per share (roughly $131.4 million) and the cancellation of multiple tranches of vested stock options with exercise prices ranging from $3.42 to $22.77, each converted into a cash payment equal to $31.50 minus the option strike price, multiplied by the number of underlying shares. In addition, several restricted stock unit awards totaling 17,626 units were cancelled and converted into cash at $31.50 per unit. Following the merger-related cash-out of his common shares, options and RSUs, McEnany no longer holds equity in the company, which is consistent with a going‑private or change‑of‑control transaction rather than an open‑market trade.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000179

Alert Tier

6